SCM
AGIO icon

Stevens Capital Management’s Agios Pharmaceuticals AGIO Stock Holding History

Stevens Capital Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-3,523
Closed -$332K – 994
2015
Q1 		$332K Buy
+3,523
New +$395K 0.01% 707

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
FV2GP
Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
CGT
Capital Guardian Trust Los Angeles, California $7.42B AUM 13.6% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Stevens Capital Management's AGIO Position: Q2 2015 in Review

Stevens Capital Management sold out of Agios Pharmaceuticals (AGIO) in Q2 2015, closing a stake of 3,523 shares — an estimated $332K sold.

Stevens Capital Management first reported a position in AGIO in Q1 2015 and held it in 1 quarter. The position peaked at $332K in Q1 2015. 161 funds tracked by Wall St. Rank hold AGIO as of Q2 2015.

  • Stevens Capital Management reported no remaining Agios Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Stevens Capital Management sold 3,523 Agios Pharmaceuticals shares in Q2 2015, an estimated $332K.
  • Stevens Capital Management first reported a position in Agios Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • Stevens Capital Management's Agios Pharmaceuticals position peaked at $332K in Q1 2015.
  • 161 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2015.

Based on Stevens Capital Management's 13F filing for Q2 2015, filed 11 Aug 2015.